Abstract
Higher organisms such as mammals exist in a symbiotic relationship with their gut microbiota, formed from a diverse and highly metabolically active consortium of species. The gut microbiota, in addition to their ability to process dietary derived material, are also capable of performing a range of biotransformations on xenobiotics, such as drugs and their metabolites, in ways that can affect absorption and bioavailability. The potential for the gut microflora to influence drug metabolism and toxicity in unexpected ways is discussed.
Keywords: Drug metabolism, bioavailability, gut microbiota, superorganisms, population differences, diet
Current Pharmaceutical Design
Title: The Role of Gut Microbiota in Drug Response
Volume: 15 Issue: 13
Author(s): I. D. Wilson and J. K. Nicholson
Affiliation:
Keywords: Drug metabolism, bioavailability, gut microbiota, superorganisms, population differences, diet
Abstract: Higher organisms such as mammals exist in a symbiotic relationship with their gut microbiota, formed from a diverse and highly metabolically active consortium of species. The gut microbiota, in addition to their ability to process dietary derived material, are also capable of performing a range of biotransformations on xenobiotics, such as drugs and their metabolites, in ways that can affect absorption and bioavailability. The potential for the gut microflora to influence drug metabolism and toxicity in unexpected ways is discussed.
Export Options
About this article
Cite this article as:
Wilson D. I. and Nicholson K. J., The Role of Gut Microbiota in Drug Response, Current Pharmaceutical Design 2009; 15 (13) . https://dx.doi.org/10.2174/138161209788168173
DOI https://dx.doi.org/10.2174/138161209788168173 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Platelet Concentrates for Topical Use: Bedside Device and Blood Transfusion Technology. Quality and Versatility
Current Pharmaceutical Biotechnology Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design 10 Years of SELDI: What Have we Learnt?
Current Proteomics From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Multifunctionalized Microbubbles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Process Development of Piezoelectric Micro Power Generator for Implantable Biomedical Devices
Micro and Nanosystems Virtual Screening Strategies in Medicinal Chemistry: The State of the Art and Current Challenges
Current Topics in Medicinal Chemistry Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research